Stability and binding effects of silver(I) complexes at lipoxygenase-1. (August 2015)

• Record Type: Journal Article
• Authors: Vrontaki, Eleni; Leonis, Georgios; Avramopoulos, Aggelos; Papadopoulos, Manthos G.; Simčič, Mihael; Grdadolnik, Simona Golič; Afantitis, Antreas; Melagraki, Georgia; Hadjikakou, Sotiris K.; Mavromoustakos, Thomas
• Is Part Of: Journal of enzyme inhibition and medicinal chemistry. Volume 30:Number 4(2015:Aug.)
• Page Start: 539
• Page End: 549
• Publication Date: 2015-08
• Subjects: Enzyme inhibitors -- Periodicals; Enzyme Inhibitors -- periodicals; Biochemistry -- periodicals; 572.7
• DOI: 10.3109/14756366.2014.951348
• Languages: English
• ISSNs: 1475-6366

Abstract

<abstract> <title>Abstract</title> <p>An anti-inflammatory complex of Ag(I), namely [Ag(tpp)₃(asp)](dmf) [tpp = triphenylphosphine, aspH = aspirin, dmf = <italic>N, N</italic>-dimethylformamide], was synthesized in an attempt to develop novel metallotherapeutic molecules. STD ¹H NMR experiments were used to examine if this complex binds to LOX-1. The ¹H NMR spectra in buffer Tris/D₂O betrayed the existence of two complexes: the complex of aspirin and the complex of salicylic acid produced after deacetylation of aspirin. Nevertheless, the STD spectra showed that only the complex of salicylic acid is bound to the enzyme. Molecular docking and dynamics were used to complement our study. The complexes were stabilized inside a large LOX-1 cavity by establishing a network of hydrogen bonds and steric interactions. The complex formation with salicylic acid was more favorable. The <italic>in silico</italic> results provide a plausible explanation of the experimental results, which showed that only the complex with salicylic acid enters the binding cavity.</p> </abstract>